Literature DB >> 28220249

[Adjuvant radiotherapy during anti-VEGF in neovascular age-related macular degeneration].

P Rating1, M-A Freimuth2, M Stuschke3, N Bornfeld2.   

Abstract

Single adjuvant radiotherapy during anti-VEGF therapy could be in certain indications an alternative to the gold standard of sole intravitreal anti-VEGF drug injection in neovascular age-related macular degeneration. First clinical trials showed efficacy due to reduction of anti-VEGF injection numbers by 100 kV collimated beam radiotherapy. After consideration and performance of adjuvant radiotherapy, results of the course should be centrally registered in order to carry out further analysis.

Entities:  

Keywords:  Injection; Intraocular injections; Irradiation technique; Radiation injuries; Radiation retinopathy

Mesh：

Substances：

Year:  2017        PMID： 28220249     DOI： 10.1007/s00347-017-0451-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  20 in total

1.  Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.

Authors:  Susanna S Park; Inder Daftari; Theodore Phillips; Lawrence S Morse
Journal:  Retina       Date:  2012-05       Impact factor: 4.256

2.  [In Process Citation].

Authors: 
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

3.  [Radiotherapy for age-related macular degeneration: risk factors of complications, prevention and treatment of side-effects].

Authors:  M Mauget-Faÿsse; R Coquard; C Français-Maury; D Milea; C Chiquet; P Martin; P Romestaing; J P Romanet; J P Gérard
Journal:  J Fr Ophtalmol       Date:  2000-02       Impact factor: 0.818

4.  Stereotactic targeting and dose verification for age-related macular degeneration.

Authors:  Michael Gertner; Erik Chell; Kuang-Hung Pan; Steve Hansen; Peter K Kaiser; Darius M Moshfeghi
Journal:  Med Phys       Date:  2010-02       Impact factor: 4.071

5.  Proton beam irradiation for neovascular age-related macular degeneration.

Authors:  Hadi J Zambarakji; Anne Marie Lane; Eric Ezra; Danny Gauthier; Michael Goitein; Judy A Adams; John E Munzenrider; Joan W Miller; Evangelos S Gragoudas
Journal:  Ophthalmology       Date:  2006-08-28       Impact factor: 12.079

6.  Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma.

Authors:  K Gündüz; C L Shields; J A Shields; J Cater; J E Freire; L W Brady
Journal:  Arch Ophthalmol       Date:  1999-05

7.  Radiation retinopathy after external-beam irradiation: analysis of time-dose factors.

Authors:  J T Parsons; F J Bova; C R Fitzgerald; W M Mendenhall; R R Million
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-11-15       Impact factor: 7.038

8.  Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.

Authors:  Timothy L Jackson; Usha Chakravarthy; Peter K Kaiser; Jason S Slakter; Ernest Jan; Francesco Bandello; Denis O'Shaughnessy; Michael E Gertner; Linda Danielson; Darius M Moshfeghi
Journal:  Ophthalmology       Date:  2013-03-13       Impact factor: 12.079

9.  Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.

Authors:  Timothy L Jackson; Usha Chakravarthy; Jason S Slakter; Alyson Muldrew; E Mark Shusterman; Denis O'Shaughnessy; Mark Arnoldussen; Michael E Gertner; Linda Danielson; Darius M Moshfeghi
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

10.  Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).

Authors:  Pravin U Dugel; Judith D Bebchuk; Jeffrey Nau; Elias Reichel; Michael Singer; Adiel Barak; Susanne Binder; Timothy L Jackson
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079
View more
  1 in total

1.  All-trans retinoic acid increases ARPE-19 cell apoptosis via activation of reactive oxygen species and endoplasmic reticulum stress pathways.

Authors:  Juan Wu; Zhen-Ya Gao; Dong-Mei Cui; Hong-Hui Li; Jun-Wen Zeng
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.